doi:10.3389/fimmu.2020.571731 50
At standard dosing of 1 mg daily, a single vial provides approximately 50 days of treatment, translating to roughly $48-72 CAD monthly
2.2 Primary and secondary outcome measurement 2.2.1 Primary outcome measurement MDA, neopterin, and TOS in recruited groups are expected to increase at primary investigation, while catalase, paraoxonase, and TAC to decrease on admission, we hypothesized NAC could reduce MDA, neopterin, and TOS but increase catalase, paraoxonase, and TAC, 24 h after being administered
noted that patients who underwent EGD with concurrent colonoscopy had lower rates of RGC: 4% of patients who had EGD and colonoscopy had RGC, compared to 17% of patients who only underwent EGD ( p -value = 0.02) [18]